Payment overview · 2025
General Payments
$670.74
33 reported records · 8 companies
Healthcare provider profile · identity verified
Michael S. Friedman, MD
Allopathic & Osteopathic Physicians|Family Medicine · GROVETOWN, GA · NPI 1962562355
Verified facts
What the public records show
CMS Open Payments records show Michael S. Friedman, MD received $670.74 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $198.79 | 29.6% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $147.09 | 21.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $126.46 | 18.9% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $92.74 | 13.8% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.44 | 5.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.51 | 5.3% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.26 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.45 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $670.74 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $138.46 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $117.25 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $84.03 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $84.03 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $84.03 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.73 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.44 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.04 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $8.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 19 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
142 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 72 |
| Losartan Potassium | Losartan Potassium | 223 | 60 |
| Lisinopril | Lisinopril | 206 | 54 |
| Alprazolam | Alprazolam | 195 | 33 |
| Tramadol Hcl | Tramadol Hcl | 182 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 42 |
| Metformin Hcl | Metformin Hcl | 173 | 46 |
| Gabapentin | Gabapentin | 168 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 22 |
| Mounjaro | Tirzepatide | 142 | 19 |
| Eliquis | Apixaban | 128 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 41 |
| Simvastatin | Simvastatin | 123 | 33 |
| Omeprazole | Omeprazole | 117 | 35 |
| Meloxicam | Meloxicam | 116 | 30 |
| Trazodone Hcl | Trazodone Hcl | 116 | 32 |
| Clonazepam | Clonazepam | 111 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 29 |
| Lorazepam | Lorazepam | 108 | 17 |
| Sertraline Hcl | Sertraline Hcl | 106 | 29 |
| Alendronate Sodium | Alendronate Sodium | 105 | 32 |
| Furosemide | Furosemide | 99 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | 15 |
| Prednisone | Prednisone | 95 | 64 |
| Ozempic | Semaglutide | 89 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 19 |
| Carvedilol | Carvedilol | 79 | 22 |
| Potassium Chloride | Potassium Chloride | 78 | 23 |
| Estradiol | Estradiol | 77 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 22 |
| Famotidine | Famotidine | 72 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 24 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Allopurinol | Allopurinol | 63 | 14 |
| Glimepiride | Glimepiride | 61 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 13 |
| Celecoxib | Celecoxib | 58 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Finasteride | Finasteride | 56 | 15 |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 15 |
| Spironolactone | Spironolactone | 52 | 13 |
| Jardiance | Empagliflozin | 49 | 11 |
| Donepezil Hcl | Donepezil Hcl | 48 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 17 |
| Pregabalin | Pregabalin | 46 | 16 |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 13 |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Valsartan | Valsartan | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 12 |
| Temazepam | Temazepam | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Torsemide | Torsemide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $670.74 · 33 records | Novo Nordisk Inc | ABRYSVO, AREXVY, BEXSERO, COMIRNATY, ELIQUIS, ImmunoCAP, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error